Member Info for LTbeliever

Sol, IMO Bob is busy with all the products launches etc, interviews will surely follow in a few weeks once the Co has turned a corner. Now a bit premature but next phase will be MET's promotion.

Sells at 0.70, all buys above 0.73 for the past few weeks; the algorithm just reads as sells any trades below the mid-price of 0.75.

No worries though, MET will fly next month once the interims are released and it becomes obvious that it's both profitable now and cash-generative IMO.

Https://www.modernwater.com/wp-content/uploads/2025/07/MW-Toxicity-Brochure-A4-Print-28-07-2025.pdf

3 key points - 2900+ MTox LXs in operation (good for reagent use)

4week cycles for CTM = 13 reagent refills

MTox FX also used for pathogen detection - IMO FXs will be flying off the shelf in H2.

Anything worth sharing here by anyone who went?

bobbust?

Huge vote of confidence; Co will fully repay 2mln+ (incl. interest) over the next 2 years, signalling NO PLACING needed and BIG RISE IN expected revenues; just to pay off 1mln per annum implies at least 2mln rise in Sales (additional to the 2024 total of 4mln) and a rise in Gross Margins; so we are looking at 6ml+ Revenues for 2025; in 2 weeks the Interims should show at least 3 mln in Sales over H1 2025 IMO; SP should rise further then.

If not mistaken, CTMs are only for toxicity monitoring; Bobbust, maybe you can ask this one too?

Https://www.investegate.co.uk/announcement/rns/aptamer-group--apta/wastewater-monitoring-system-installed-in-uk/7057259

actually, this cooperation goes back 3 years, it started with COVID. It'd be quite realistic to see in 2-3 years most of UK-treated waste water passing through METIR's 24/7 equipment (using APTA's optimers as disease scanners). Already METIR has installed such a system (27 CTMs) for Doha's water monitoring (24/7); not sure though if CTMs are using optimers.

The below is possibly "small change" compared to all the stuff APTA already is gearing for, but just shows that news can come on this one too, in a few weeks, now that the fund raise by MET has been completed..DYOR

"Funding to move towards commercial testing for the Company's novel prototype Pathogen Detector in conjunction with Aptamer Group plc initially for rapid on-line detection of Cryptosporidium, the primary pathogen found in sewage polluted potable water in the UK and elsewhere"

https://www.lse.co.uk/rns/MET/fundraise-qxkjl5aw7b70mpd.html

4. commercialise the PFAs equipment?

Tnx bobbust; we may even get a bullish RNS on Tuesday morning, I reckon that we have already reached B/E on a monthly basis.

Questions?

1. From the 3000+ MTox machines (sold over the past 10-15 years), how many are still in operation / being serviced? Is the Co planning to upgrade them/offer incentives so that more reagents can be consumed?

2. Has the figure of 3 MTox LX's sold very week pre-fund raise, now increased to how many? How many LXs do they expect to sell by Y/E?

3. Do they have orders for the FX?

4. Do they expect to commercialise / sign a deal with the US water safeguarding co by Y/E?

Seems nobody going is on this BB, or wants to announce it :)

Anyone going next week? If so, should we write some questions for him/her, to raise at the AGM?

We can list questions on this thread if you all agree; then, we can get the answers at the AGM maybe?

FWIW

https://x.com/patviera/status/1951795553714524358

https://uk.advfn.com/stock-market/london/aptamer-APTA/share-chat

Also ignored any additional CTM sales in 2026 and receipt of the warranty money (114k over 2 years), plus - importantly - 24/7 reagent use by the 27 CTMs in Doha which should be active at least for 3 months in H2 2025.

At eoDec 2024, cash was 2mln; eoJune 2025 cash was 1.06mln; Febr 25 tax refund 200k received + 400k gross profit (6 months), so cash outflow of £1.6mln appx for 6 months (if not mistaken!).

Cash at July 1st 2025 (+Placing) is £3mln, +200k (?) tax refund in early 2026, plus 600-800k gross profit (at a minimum?) to eoJune 2026 (ignoring any licensing income or upfront payments); cash burn £3mln over 12 months ? this leaves APTA with minimum of £1mln cash on 30 June 2026, in a worst case scenario of no licensing payments and same FFS fees as the prior year. IMO

And I have ignored any FX sales, which can be ordered now, even for our Canada agent.

https://geneq.com/environment/en/product/modern-water/microtox-fx-analyzer-12350

https://www.modernwater.com/monitoring/toxicity/portable-microtox-fx/

£931k minus the 155k of reagent sales = 776k;

sales of 34 MTx LX by 30 June (as per 29 May RNS) imply a Sales Price of appx£20k per LX? leaving £100k appx for other services/products (or £23k per LX, if no other product sales);

Thus, for H2 we have as a minimum: £386k from Qatar (by Sept end),

3-4 LX sales weekly (x 26 to Y/E) i.e. 80-100 @20k = 1.6-2mln, plus reagent sales of 200-300k, plus SRB kit sales (50-100k?) gives us £2.4-2.8 mln!

GM of 50% (might be higher) i.e.1.2-1.4mln, minus expenses of £6-700k (100k pm) leaves a Net Profit of MIN £500k-700k for H2 2025. IMO

A loss of £300-400k in H1 will leave an EBITDA of £200-300k for FY2025. And FY2026 might give an EBITDA equal to the current Mkt cap! All IMO, feel free to question my assumptions.

IMO we are easily headed for 2mln Revenue in H2, and positive cashflow, ignoring any licensing deals for the PD detector and/or a PFAS one. That'd mean 3mln for the FY, making it the most productive year ever.

Today's trade activity may actually be connected to the 2nd CLN extension/ arrangement. If also to be settled over a 2-3 year horizon, it'd be very positive.

Interims due in September, should show positive cashflow IMO. Auditors IMO would not allow release of 2024 AFS without having a firm indication that both CLNs can be extended/ paid off.